Literature DB >> 23722831

Chronic scopolamine-injection-induced cognitive deficit on reward-directed instrumental learning in rat is associated with CREB signaling activity in the cerebral cortex and dorsal hippocampus.

Zhe Shi1, Lingling Chen, Sidi Li, Shanguang Chen, Xiuping Sun, Lihua Sun, Yinghui Li, Jianguo Zeng, Yiran He, Xinmin Liu.   

Abstract

RATIONALE: Scopolamine, a nonselective muscarinic receptor antagonist, has been used in experimental animal models of dementia. It has been demonstrated to disrupt performances in a battery of behavioral tests. However, no attempt has been made to determine how scopolamine-treated animals would respond to a series of reward-directed instrumental learning (RDIL) tasks.
OBJECTIVES: The present study was designed to investigate the effects of chronic intraperitoneal injection of scopolamine in Wistar rats on RDIL, as well as on the expression of memory-related molecules in the dorsal hippocampus (DH) and cerebral cortex (CCx).
METHODS: The effects of the pretraining injection of scopolamine on the acquisition of instrumental response (experiment 1) were first investigated. Then, the effects of post-training manipulation on the maintenance of instrumental response and the responses to changes in contingency degradation and signal discrimination were assessed (experiment 2). Finally, the expression of cyclic AMP response element-binding protein (CREB), phosphorylated CREB, and brain-derived neurotrophic factor in the DH and CCx were examined using Western blotting and enzyme-linked immunosorbent assay.
RESULTS: The acquisition of instrumental conditioning is more vulnerable than its maintenance. The 3.0-mg/kg dose of scopolamine rendered rats unable to make adaptive changes in facing contingency degradation and correct responses in signal discrimination tasks. Furthermore, CREB signaling was inactivated by pretraining scopolamine treatment in both the DH and CCx. Nevertheless, this pathway was selectively suppressed by post-training treatment only in the CCx during memory reconsolidation.
CONCLUSIONS: The results suggest that scopolamine-induced cognitive deficits on RDIL are related to the distinguishing alteration of CREB signaling in the DH and CCx.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722831     DOI: 10.1007/s00213-013-3149-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  82 in total

1.  Time-dependent reorganization of brain circuitry underlying long-term memory storage.

Authors:  B Bontempi; C Laurent-Demir; C Destrade; R Jaffard
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

Review 2.  Memory--a century of consolidation.

Authors:  J L McGaugh
Journal:  Science       Date:  2000-01-14       Impact factor: 47.728

Review 3.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 4.  Goal-directed instrumental action: contingency and incentive learning and their cortical substrates.

Authors:  B W Balleine; A Dickinson
Journal:  Neuropharmacology       Date:  1998 Apr-May       Impact factor: 5.250

Review 5.  The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

6.  Scopolamine prevents retrograde memory interference between two different learning tasks.

Authors:  M G Blake; M M Boccia; M C Krawczyk; C M Baratti
Journal:  Physiol Behav       Date:  2010-11-29

Review 7.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

8.  Possible interaction of cholinergic and GABAergic systems between MS and CA1 upon memory acquisition in rats.

Authors:  Behnam Yousefi; Mohammad Nasehi; Fatemeh Khakpai; Mohammad Reza Zarrindast
Journal:  Behav Brain Res       Date:  2012-08-13       Impact factor: 3.332

Review 9.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

10.  Schemas and memory consolidation.

Authors:  Dorothy Tse; Rosamund F Langston; Masaki Kakeyama; Ingrid Bethus; Patrick A Spooner; Emma R Wood; Menno P Witter; Richard G M Morris
Journal:  Science       Date:  2007-04-06       Impact factor: 47.728

View more
  11 in total

1.  The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.

Authors:  Lijun Zhang; Jae Hong Seo; Huan Li; Ghilsoo Nam; Hyun Ok Yang
Journal:  Br J Pharmacol       Date:  2018-07-10       Impact factor: 8.739

Review 2.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

3.  Chronic stress-induced depression requires the recruitment of peripheral Th17 cells into the brain.

Authors:  Zhuang Peng; Sha Peng; Kangguang Lin; Bin Zhao; Lai Wei; Qinhui Tuo; Duanfang Liao; Tifei Yuan; Zhe Shi
Journal:  J Neuroinflammation       Date:  2022-07-14       Impact factor: 9.587

4.  Effects of Chronic Scopolamine Treatment on Cognitive Impairments and Myelin Basic Protein Expression in the Mouse Hippocampus.

Authors:  Joon Ha Park; Hyun Young Choi; Jeong-Hwi Cho; In Hye Kim; Tae-Kyeong Lee; Jae-Chul Lee; Moo-Ho Won; Bai Hui Chen; Bich-Na Shin; Ji Hyeon Ahn; Hyun-Jin Tae; Jung Hoon Choi; Jin-Young Chung; Choong-Hyun Lee; Jun Hwi Cho; Il Jun Kang; Jong-Dai Kim
Journal:  J Mol Neurosci       Date:  2016-06-24       Impact factor: 3.444

5.  Z-Guggulsterone Improves the Scopolamine-Induced Memory Impairments Through Enhancement of the BDNF Signal in C57BL/6J Mice.

Authors:  Zhuo Chen; Chao Huang; Wenbin Ding
Journal:  Neurochem Res       Date:  2016-09-28       Impact factor: 3.996

6.  Tong Luo Jiu Nao ameliorates Aβ1-40-induced cognitive impairment on adaptive behavior learning by modulating ERK/CaMKII/CREB signaling in the hippocampus.

Authors:  Zhe Shi; Cong Lu; Xiuping Sun; Qiong Wang; Shanguang Chen; Yinghui Li; Lina Qu; Lingling Chen; Lanlan Bu; Duanfang Liao; Xinmin Liu
Journal:  BMC Complement Altern Med       Date:  2015-03-11       Impact factor: 3.659

7.  Cognitive-Enhancing Effect of Aronia melanocarpa Extract against Memory Impairment Induced by Scopolamine in Mice.

Authors:  Hyeon Yong Lee; Jin Bae Weon; Youn Sik Jung; Nam Young Kim; Myong Ki Kim; Choong Je Ma
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-30       Impact factor: 2.629

8.  Effects of chronic scopolamine treatment on cognitive impairment and neurofilament expression in the mouse hippocampus.

Authors:  Jae-Chul Lee; Joon Ha Park; Ji Hyeon Ahn; Jinseu Park; In Hye Kim; Jeong Hwi Cho; Bich Na Shin; Tae-Kyeong Lee; Hyunjung Kim; Minah Song; Geum-Sil Cho; Dae Won Kim; Il Jun Kang; Young-Myeong Kim; Moo-Ho Won; Soo Young Choi
Journal:  Mol Med Rep       Date:  2017-11-15       Impact factor: 2.952

9.  Vanillin improves scopolamine‑induced memory impairment through restoration of ID1 expression in the mouse hippocampus.

Authors:  Jae-Chul Lee; In Hye Kim; Jeong Hwi Cho; Tae-Kyeong Lee; Joon Ha Park; Ji Hyeon Ahn; Bich Na Shin; Bing Chun Yan; Jong-Dai Kim; Yong Hwan Jeon; Young Joo Lee; Moo-Ho Won; Il Jun Kang
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

10.  Cognitive-Enhancing Effect of Steamed and Fermented Codonopsis lanceolata: A Behavioral and Biochemical Study.

Authors:  Jin Bae Weon; Bo-Ra Yun; Jiwoo Lee; Min Rye Eom; Hyun-Jeong Ko; Hyeon Yong Lee; Dong-Sik Park; Hee-Chul Chung; Jae Youn Chung; Choong Je Ma
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.